文献リスト

1) 後藤信哉, 浅田祐士郎. 血栓症−やさしく, くわしく, わかりやすく. 東京: 南江堂; 2006

2) Hoshiba Y, Hatakeyama K, Tanabe T, et al. Co-localization of von Willebrand factor with platelet thrombi, tissue factor and platelets with fibrin, and consistent presence of inflammatory cells in coronary thrombi obtained by an aspiration device from patients with acute myocardial infarction. J Thromb Haemost. 2006; 4: 114-20

3) Eto K, Murphy R, Kerrigan SW, et al. Megakaryocytes derived from embryonic stem cells implicate CalDAG-GEFI in integrin signaling. Proc Natl Acad Sci U S A. 2002; 99: 12819-24

4) Nishikii H, Eto K, Tamura N, et al. Metalloproteinase regulation improves in vitro generation of efficacious platelets from mouse embryonic stem cells. J Exp Med. 2008; 205: 1917-27

5) 後藤信哉. 臨床現場におけるアスピリン使用の実際. 東京: 南江堂; 2006

6) Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17, 187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet. 1988; 2: 349-60

7) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002; 324: 71-86

8) Patrono C, Garcia Rodriguez LA, Landolfi R, et al. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med. 2005; 353: 2373-83

9) Goto S. Cardiovascular risk factors in patients at high risk of atherothrombosis: what can be learned from registries？ Thromb Haemost. 2008; 100: 611-3

10) Bhatt DL, Steg PG, Ohman EM, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA. 2006; 295: 180-9

11) Yamazaki T, Goto S, Shigematsu H, et al. Prevalence, awareness and treatment of cardiovascular risk factors in patients at high risk of atherothrombosis in Japan. Circ J. 2007; 71: 995-1003

12) Steg PG, Bhatt DL, Wilson PW, et al. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA. 2007; 297: 1197-206

13) Yamamoto T, Kuyama Y, Kozuma K, et al. Low-dose aspirin prolongs bleeding after gastric biopsy in Japanese patients. Thromb Res. 2008; 122: 722-3

14) Goto S. Are Japanese patients more prone to gastro-duodenal mucosal injury and bleeding with the use of antiplatelet agents？ Thromb Res. 2007; 120: 463-4

15) Sato H, Ishikawa K, Kitabatake A, et al. Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation: Japan Atrial Fibrillation Stroke Trial. Stroke. 2006; 37: 447-51

16) Origasa H, Goto S, Uchiyama S, et al. The Japan Thrombosis Registry for Atrial Fibrillation, Coronary or Cerebrovascular Events (J-TRACE): a nation-wide, prospective large cohort study; the study design. Circ J. 2008; 72: 991-7

17) Fujita M, Yamazaki T, Hayashi D, et al. Comparison of cardiovascular events in patients with angiographically documented coronary narrowing with combined renin-angiotensin system inhibitor plus statin versus renin-angiotensin system inhibitor alone versus statin alone (from the Japanese Coronary Artery Disease Study). Am J Cardiol. 2007; 100: 1750-3

18) Violi F, Pignatelli P. The need for a consistent definition of “aspirin resistance". J Thromb Haemost. 2006; 4: 1618-9

19) Frelinger AL 3rd, Furman MI, Linden MD, et al. Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance. Circulation. 2006; 113: 2888-96

20) Hillman RS. Platelet aspirin resistance detection and validation. J Am Coll Cardiol. 2006; 47: 2565; author reply 2566

21) Johns A, Fisher M, Knappertz V. Aspirin and clopidogrel resistance: an emerging clinical entity. Eur Heart J. 2006; 27: 1754; author reply 1754-5

22) Hankey GJ, Eikelboom JW. Aspirin resistance. Lancet. 2006; 367: 606-17

23) Szczeklik A, Musial J, Undas A, et al. Aspirin resistance. J Thromb Haemost. 2005; 3: 1655-62

24) Chen WH, Cheng X, Lee PY, et al. Aspirin resistance and adverse clinical events in patients with coronary artery disease. Am J Med. 2007; 120: 631-5

25) Gasparyan AY, Watson T, Lip GY. The role of aspirin in cardiovascular prevention: implications of aspirin resistance. J Am Coll Cardiol. 2008; 51: 1829-43

26) Madsen EH, Schmidt EB, Gehr N, et al. Testing aspirin resistance using the Platelet Function Analyzer-100: some methodological caveats and considerations. J Thromb Haemost. 2008; 6: 386-8

27) Krasopoulos G, Brister SJ, Beattie WS, et al. Aspirin “resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ. 2008; 336: 195-8

28) Snoep JD, Hovens MM, Eikenboom JC, et al. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch Intern Med. 2007; 167: 1593-9

29) Maree AO, Cox D, Fitzgerald DJ. Drug insight: aspirin resistance-fact or fashion？ Nat Clin Pract Cardiovasc Med. 2007; 4: E1; author reply E2

30) Undas A, Brummel-Ziedins KE, Mann KG. Antithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actions. Blood. 2007; 109: 2285-92

31) Scheen AJ, Legrand D. Aspirin and clopidogrel resistance in patients with diabetes mellitus. Eur Heart J. 2006; 27: 2900; author reply 2900-1

32) Patrono C, Rocca B. Aspirin: promise and resistance in the new millennium. Arterioscler Thromb Vasc Biol. 2008; 28: s25-32

33) Ohmori T, Yatomi Y, Nonaka T, et al. Aspirin resistance detected with aggregometry cannot be explained by cyclooxygenase activity: involvement of other signaling pathway(s) in cardiovascular events of aspirin-treated patients. J Thromb Haemost. 2006; 4: 1271-8

34) Patrono C, Goto S. Aspirin “Resistance". International Review of Thrombosis. 2008; 3: 28-35

35) Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007; 357: 2001-15

36) Goto S, Tamura N, Ishida H, et al. Dependence of platelet thrombus stability on sustained glycoprotein IIb/IIIa activation through adenosine 5'-diphosphate receptor stimulation and cyclic calcium signaling. J Am Coll Cardiol. 2006; 47: 155-62

37) Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001; 358: 527-33

38) Cuisset T, Frere C, Quilici J, et al. Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting. J Am Coll Cardiol. 2006; 48: 1339-45

39) von Beckerath N, Taubert D, Pogatsa-Murray G, et al. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial. Circulation. 2005; 112: 2946-50

40) Bhatt DL, Roe MT, Peterson ED, et al. Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. JAMA. 2004; 292: 2096-104

41) Bhatt DL, Flather MD, Hacke W, et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol. 2007; 49: 1982-8

42) Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006; 354: 1706-17

43) Connolly S, Pogue J, Hart R, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006; 367: 1903-12

44) Frelinger AL 3rd, Jakubowski JA, Li Y, et al. The active metabolite of prasugrel inhibits adenosine diphosphate- and collagen-stimulated platelet procoagulant activities. J Thromb Haemost. 2008; 6: 359-65

45) Wallentin L, Varenhorst C, James S, et al. Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J. 2008; 29: 21-30

46) Williams ET, Jones KO, Ponsler GD, et al. The biotransformation of prasugrel, a new thienopyridine prodrug, by the human carboxylesterases 1 and 2. Drug Metab Dispos. 2008; 36: 1227-32

47) Serebruany VL, Alberts MJ, Hanley DF. Prasugrel in the poststroke cohort of the TRITON Trial: the clear and present danger. Cerebrovasc Dis. 2008; 26: 93-4

48) Antman EM, Wiviott SD, Murphy SA, et al. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis. J Am Coll Cardiol. 2008; 51: 2028-33

49) Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet. 2007; 369: 1090-8

50) Shinohara Y, Nishimaru K, Sawada T, et al. Sarpogrelate-Aspirin Comparative Clinical Study for Efficacy and Safety in Secondary Prevention of Cerebral Infarction (S-ACCESS): A randomized, double-blind, aspirin-controlled trial. Stroke. 2008; 39: 1827-33

51) Ishii H, Kumada Y, Toriyama T, et al. Cilostazol improves long-term patency after percutaneous transluminal angioplasty in hemodialysis patients with peripheral artery disease. Clin J Am Soc Nephrol. 2008; 3: 1034-40

52) Iida O, Nanto S, Uematsu M, et al. Cilostazol reduces restenosis after endovascular therapy in patients with femoropopliteal lesions. J Vasc Surg. 2008; 48: 144-9

53) Hiatt WR, Money SR, Brass EP. Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: A Study in Long-term Effects). J Vasc Surg. 2008; 47: 330-6

54) Shinohara Y, Gotoh F, Tohgi H, et al. Antiplatelet cilostazol is beneficial in diabetic and/or hypertensive ischemic stroke patients. Subgroup analysis of the cilostazol stroke prevention study. Cerebrovasc Dis. 2008; 26: 63-70

55) Huang Y, Cheng Y, Wu J, et al. Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study. Lancet Neurol. 2008; 7: 494-9

56) Lee SW, Park SW, Hong MK, et al. Triple versus dual antiplatelet therapy after coronary stenting: impact on stent thrombosis. J Am Coll Cardiol. 2005; 46: 1833-7

57) Lee SW, Park SW, Kim YH, et al. Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Diabetic Patients). J Am Coll Cardiol. 2008; 51: 1181-7

58) Angiolillo DJ, Capranzano P, Goto S, et al. A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study. Eur Heart J. 2008; 29: 2202-11

59) Goto S. Cilostazol: potential mechanism of action for antithrombotic effects accompanied by a low rate of bleeding. Atheroscler Suppl. 2005; 6: 3-11

60) Gurbel PA, Serebruany VL. Oral platelet IIb/IIIa inhibitors: from attractive theory to clinical failures. J Thromb Thrombolysis. 2000; 10: 217-20

61) Ezumi Y, Shindoh K, Tsuji M, et al. Physical and functional association of the Src family kinases Fyn and Lyn with the collagen receptor glycoprotein VI-Fc receptor gamma chain complex on human platelets. J Exp Med. 1998; 188: 267-76

62) Chackalamannil S, Wang Y, Greenlee WJ, et al. Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity. J Med Chem. 2008; 51: 3061-4

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp